Cipla To Scale Up Remdesivir Production Two-Fold To Meet ‘Unprecedented Demand’ For The Drug
Cipla To Scale Up Remdesivir Production Two-Fold To Meet ‘Unprecedented Demand’ For  The DrugA pharmacy in Hyderabad, Telangana (A Prabhakar Rao/The India Today Group/Getty Images)

Pharmaceutical company Cipla on Tuesday (13 April) said it has scaled up the production of remdesivir by two times from the last wave of the pandemic.

As the demand for the drug surges, the government has prohibited the exports of remdesivir injection and its active pharmaceutical ingredients (API).

"Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," the company said in a statement.

"To ensure fair and equitable access, we are working with the regulatory authorities to restrict the supply of the drug only to hospital channels and especially those regions with a high burden of severe Covid-19," Cipla said.

On Tocilizumab, the company said that given the spike in cases and surge in demand, it is facing a shortage and working closely with its partner in taking necessary steps to ensure the availability of the drug.

"We expect intermittent supplies as the demand outstrips supply with some more receipts at the earliest," it added.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber